Angiogenesis inhibitors in the treatment of colorectal cancer

Seminars in Oncology

Volumn 31, Issue SUPPL. 17, 2004, Pages 10-16

  Iqbal, Syma ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2C3; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANGIOZYME; AS 1404; AVE 8062A; BEVACIZUMAB; CILENGITIDE; COMBRETASTATIN A4; CP 574; CP 632; FLUOROURACIL; FOLINIC ACID; HUMV 833; IMC 1121B; IRINOTECAN; MONOCLONAL ANTIBODY LM 609; N ACETYLCOLCHINOL PHOSPHATE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; OXALIPLATIN; RIBOZYME; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGINA PECTORIS; ANGIOGENESIS; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG SAFETY; EDEMA; EPISTASIS; EPISTAXIS; FATIGUE; HEART INFARCTION; HUMAN; HYPERTENSION; LUNG EMBOLISM; MOUTH DISEASE; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SKIN DISCOLORATION; STROKE; SURVIVAL RATE; SYSTOLIC HYPERTENSION; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TUMOR GROWTH; VEIN THROMBOSIS; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 13244291424     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.11.029     Document Type: Article

References (38)

1. R.M. Goldberg, D.J. Sargent, R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
2. C. Tournigand, T. Andre, E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer A randomized GERCOR study J Clin Oncol 22 2004 229 237
3. N. Ferrara, K. Carver-Moore, H. Chen Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene Nature 380 1996 439 442
4. N. Ferrara Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis Therapeutic implications Semin Oncol 29 suppl 16 2002 10 14
5. N. Ferrara, T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25
6. D. Fukumura, T. Gohongi, A. Kadambi Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability Proc Natl Acad Sci U S A 98 2001 2604 2609
7. M.J. Karkkainen, P. Haiko, K. Sainio Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins Nat Immunol 5 2004 74 80
8. T. Makinen, T. Veikkola, S. Mustjoki Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3 EMBO J 20 2001 4762 4773
9. M. Toi, S. Hoshina, T. Takayanagi Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer Jpn J Cancer Res 85 1994 1045 1049
10. R.S. Warren, H. Yuan, M.R. Matli Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis J Clin Invest 95 1995 1789 1797
11. K.J. Kim, B. Li, J. Winer Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841 844
12. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy A new paradigm for combination therapy Nat Med 7 2001 987 989
13. G. Gasparini, A.L. Harris Clinical importance of the determination of tumor angiogenesis in breast carcinoma Much more than a new prognostic tool J Clin Oncol 13 1995 765 782
14. P. O'Dwyer Expanding targets in antiangiogenic therapy 2004 (personal communication)
15. M. Fanelli, N. Locopo, D. Gattuso Assessment of tumor vascularization Immunohistochemical and non-invasive methods Int J Biol Markers 14 1999 218 231
16. P.B. Vermeulen, G. Gasparini, S.B. Fox Quantification of angiogenesis in solid human tumours An international consensus on the methodology and criteria of evaluation Eur J Cancer 32A 1996 2474 2484
17. J.M. Wood, G. Bold, E. Buchdunger PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 2000 2178 2189
18. M.S. Gee, S. Makonnen, K. al-Kofahi Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition Cancer Res 63 2003 8073 8078
19. C.G. Willett, Y. Boucher, E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
20. B. Morgan, A.L. Thomas, J. Drevs Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases Results from two phase I studies J Clin Oncol 21 2003 3955 3964
21. L.S. Rosen Inhibitors of the vascular endothelial growth factor receptor Hematol Oncol Clin North Am 16 2002 1173 1187
22. P. Borgstrom, D.P. Gold, K.J. Hillan Importance of VEGF for breast cancer angiogenesis in vivo Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin Anticancer Res 19 1999 4203 4214
23. M.S. Gordon, K. Margolin, M. Talpaz Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 2001 843 850
24. Genentech Drug warning issued July 2004 2004 Genentech Inc South San Francisco, CA
25. F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
26. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
27. A. Benson, P. Catalano, N. Meropol Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC) An interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200 Proc Am Soc Clin Oncol 22 2003 243 (abstr 975)
28. B. Giantonio, H. Chen, P. Catalano Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200 Proc Am Soc Clin Oncol 23 2004 199 (abstr 3017)
29. H. Chen, M. Mooney, M. Boron Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies An NCI Treatment Referral Center trial (TRC-0301) Proc Am Soc Clin Oncol 23 2004 249 (abstr 3515)
30. J. Drevs Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastases Proc Am Soc Clin Oncol 22 2004 284 (abstr 1142)
31. W. Steward, A. Thomas, B. Morgan Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 23 2004 259 (abstr 3556)
32. N. Schleucher, T. Trarbach, U. Jumker Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 23 2004 260 (abstr 3558)
33. E. Raymond, S. Faivre, K. Vera Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers Proc Am Soc Clin Oncol 22 2003 192 (abstr 769)
34. M. Prewett, J. Huber, Y. Li Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors Cancer Res 59 1999 5209 5218
35. J.A. Posey, T.C. Ng, B. Yang A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma Clin Cancer Res 9 2003 1323 1332
36. D.E. Weng, N. Usman Angiozyme a novel angiogenesis inhibitor Curr Oncol Rep 3 2001 141 146
37. A. Venook, H. Hurwitz, C. Cunningham Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1 Results of a phase II trial of a ribozyme targeting the pre-mRNA of VEGFR-1 (angiozyme), in combination with chemotherapy Proc Am Soc Clin Oncol 22 2003 256 (abstr 1025)
38. L.B. Saltz, J.V. Cox, C. Blanke Irinotecan Study Group Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 343 2000 905 914